NIOSHTIC-2 Publications Search

Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women.

Zhang Y; Martin SW; Rose CE Jr.; Biagini RE; Franzke LH; Smith JP; Sammons DL; Robertson SA; McNeil MM

Pharmacoepidemiol Drug Saf 2008 Nov; 17(11):1060-1067

https://doi.org/10.1002/pds.1657

20034697

Background: in 2002, CDC initiated the Anthrax Vaccination Program (AVP) to provide voluntary pre-exposure anthrax vaccination for individuals at high risk for exposure to Bacillus anthracis spores. The AVP offered an opportunity to investigate hypothesized reasons for a reported gender difference in injection site adverse events (AEs) following anthrax vaccine adsorbed (AVA). Objectives: to evaluate in women the impact of body mass index (BMI), pre-vaccination serum progesterone levels, and pre-vaccination anti-anthrax protective antigen immunoglobulin G concentrations (anti-PA IgG) on the occurrence of AEs following subcutaneous AVA vaccination. Methods: participants' BMI was determined at enrollment. Also, pre-vaccination blood samples were assayed for serum progesterone and anti-PA IgG. Post-vaccination solicited AEs were recorded by participants using a 4-day diary card. Results: obese group had an elevated risk for arm soreness. Decreased pre-vaccination serum progesterone level was associated with arm swelling. Increased pre-vaccination anti-PA IgG was associated with itching on the arm; and within the obese group, was associated with arm swelling, lump or knot, redness, soreness, and warmth. Conclusions In AVA vaccinated women, obesity was associated with arm soreness and decreased pre-vaccination serum progesterone levels were associated with increased rate of arm swelling. Increased pre-vaccination anti-PA IgG may be associated with an increased frequency of itching on the arm, and in obese women, may increase the occurrence of arm swelling, lump or knot, redness, and warmth. Administering AVA according to a woman's menstrual phase may reduce the occurrence of certain injection site reactions.

Vaccines; Immune-reaction; Immune-system; Immunological-tests; Biological-effects; Biological-factors; Body-weight; Women

Michael M. McNeil, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS C-25, Atlanta, GA 30333

PDSAEA

20081101

Journal Article

mmm2@cdc.gov

2009

11

1053-8569

DART

Healthcare and Social Assistance; Manufacturing

Pharmacoepidemiology and Drug Safety

OH; GA